Висцеральный лейшманиоз у детей (собственные результаты и анализ литературы)
Висцеральный лейшманиоз у детей (собственные результаты и анализ литературы)
Волкова Г.И., Смирнова М.И., Делягин В.М. Висцеральный лейшманиоз у детей (собственные результаты и анализ литературы). Педиатрия. Consilium Medicum. 2020; 3: 80–83. DOI: 10.26442/26586630.2020.3.200344
DOI: 10.26442/26586630.2020.3.200344
________________________________________________
DOI: 10.26442/26586630.2020.3.200344
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Лейшманиоз – тропическая паразитарная инфекция с предпочтительным поражением детей. Лейшманиоз, воспринимаемый как инфекция жарких и влажных регионов, не всегда учитывается при дифференциально-диагностическом поиске у лихорадящих детей со спленомегалией, степень которой превалирует над печеночной анемией. Географический фактор во внимание не принимается. В наших наблюдениях срок от первых симптомов до диагноза колебался от 0,5 до 17 мес. Диагноз подтверждается результатами костномозговой пункции, иммунологическими пробами. Лечение основывается на применении препаратов сурьмы. Нередко регистрируются побочные реакции в виде повышения печеночных ферментов, билирубинемии, анемии. Профилактика – предупреждение укусов москитами.
Ключевые слова: дети, лейшманиоз, диагностика, лечение, профилактика.
Key words: children, leishmaniasis, diagnosis, treatment, prevention.
Ключевые слова: дети, лейшманиоз, диагностика, лечение, профилактика.
________________________________________________
Key words: children, leishmaniasis, diagnosis, treatment, prevention.
Список литературы
1. Aronson N, Copeland N, Magill A. Leishmania Species: Visceral (Kala-Azar), Cutaneous, and Mucosal Leishmaniasis. In: Benner J, Dolin R, Blaser M (Eds.) Mandell, Douglas and Bennett’s principles and practice of infectious diseases. 9th Ed. 2020; 3321–40.e4.
2. Заславский Д.В., Андриенко Е.М., Александрова И.Ю. и др. Верификация лейшманиоза кожи. Вестник дерматологии и венерологии. 2014; 5: 91–5.
[Zaslavskii D.V., Andrienko E.M., Aleksandrova I.Iu. et al. Verification of cutaneous leishmaniasis. Vestnik dermatologii i venerologii. 2014; 5: 91–5 (in Russian).]
3. Hotez P, Lo N. Neglected tropical diseases: public health control programs and mass drug administration. In: Ryan E, Hill D, Solomin T et al. (Eds.) Hunter’s Tropical Medicine and Emerging Infectious Diseases. 2020. 10th Ed.; 209–13.
4. Garcia L. Leishmaniasis. In: Cherry J, Harrison G, Kaplan Sh et al. (Eds.) Feigin and cherry’s textbook of pediatric infectious diseases. 8th Ed. 2019; 2178–86.e2.
5. Leishmaniasis. 2014. http://www.who.int/topics/leishmaniasis/en/
6. Murray H, Berman J, Davies C et al. Advances in leishmaniasis. Lancet 2005; 366 (9496): 1561–77.
7. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Centers for Diseases Control and Prevention. https://www.cdc.gov/parasites/leishmaniasis/epi.html
8. Gradoni L. Leishmaniasis. In: Kellerman R, Rakel D (Eds.). Conn’s Current Therapy. 2020; 577–80.
9. De Menezes J, Koushik A, Das S et al. Leishmania infection inhibits macrophage motility by altering F-actin dynamics and the expression of adhesion complex proteins. Cell Microbiol 2017; 19 (3). DOI: 10.1111/cmi.12668
10. Ready P. Biology of phlebotomine sand flies as vectors of disease agents. An Rev Entomol 2013; 58: 227–50.
11. Pace D. Leishmaniasis. J Infect. 2014; 69; Suppl. 1: 10–8. DOI: 10.1016/j.jinf.2014.07.016
12. Hewitt S, Reyburn H, Ashford R, Rowland M. Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: vertical distribution of cases in apartament blocks. Transact Royal Society Tropical Med Hyg 1998; 92 (3): 273–4.
13. World Health Organization (WHO). First WHO report on neglected tropical diseases 2010: working to overcome the global impact of neglected tropical diseases. Geneva, 2010.
14. Kevric I, Cappel M, Keeling J. New World and Old World Leishmania Infections. A Practical Review. Dermatol Clin 2015; 33 (3): 579–93.
15. Banuls A, Hide M, Pruqnolle F. Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol 2007; 64: 1–109.
16. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5 (11): 873–82.
17. Sakthianandeswaren A, Foote S, Handman E. The role of host genetics in leishmaniasis. Trends Parasitol 2009; 25 (8): 383–91.
18. Zhang W, Matlashewski G. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol 2001; 39 (4): 935–48.
19. Okwor I, Uzonna J. Social and Economic Burden of Human Leishmaniasis. Am J Trop Med Hyg 2016; 94 (3): 489–93.
2. Zaslavskii D.V., Andrienko E.M., Aleksandrova I.Iu. et al. Verification of cutaneous leishmaniasis. Vestnik dermatologii i venerologii. 2014; 5: 91–5 (in Russian).
3. Hotez P, Lo N. Neglected tropical diseases: public health control programs and mass drug administration. In: Ryan E, Hill D, Solomin T et al. (Eds.) Hunter’s Tropical Medicine and Emerging Infectious Diseases. 2020. 10th Ed.; 209–13.
4. Garcia L. Leishmaniasis. In: Cherry J, Harrison G, Kaplan Sh et al. (Eds.) Feigin and cherry’s textbook of pediatric infectious diseases. 8th Ed. 2019; 2178–86.e2.
5. Leishmaniasis. 2014. http://www.who.int/topics/leishmaniasis/en/
6. Murray H, Berman J, Davies C et al. Advances in leishmaniasis. Lancet 2005; 366 (9496): 1561–77.
7. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Centers for Diseases Control and Prevention. https://www.cdc.gov/parasites/leishmaniasis/epi.html
8. Gradoni L. Leishmaniasis. In: Kellerman R, Rakel D (Eds.). Conn’s Current Therapy. 2020; 577–80.
9. De Menezes J, Koushik A, Das S et al. Leishmania infection inhibits macrophage motility by altering F-actin dynamics and the expression of adhesion complex proteins. Cell Microbiol 2017; 19 (3). DOI: 10.1111/cmi.12668
10. Ready P. Biology of phlebotomine sand flies as vectors of disease agents. An Rev Entomol 2013; 58: 227–50.
11. Pace D. Leishmaniasis. J Infect. 2014; 69; Suppl. 1: 10–8. DOI: 10.1016/j.jinf.2014.07.016
12. Hewitt S, Reyburn H, Ashford R, Rowland M. Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: vertical distribution of cases in apartament blocks. Transact Royal Society Tropical Med Hyg 1998; 92 (3): 273–4.
13. World Health Organization (WHO). First WHO report on neglected tropical diseases 2010: working to overcome the global impact of neglected tropical diseases. Geneva, 2010.
14. Kevric I, Cappel M, Keeling J. New World and Old World Leishmania Infections. A Practical Review. Dermatol Clin 2015; 33 (3): 579–93.
15. Banuls A, Hide M, Pruqnolle F. Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol 2007; 64: 1–109.
16. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5 (11): 873–82.
17. Sakthianandeswaren A, Foote S, Handman E. The role of host genetics in leishmaniasis. Trends Parasitol 2009; 25 (8): 383–91.
18. Zhang W, Matlashewski G. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol 2001; 39 (4): 935–48.
19. Okwor I, Uzonna J. Social and Economic Burden of Human Leishmaniasis. Am J Trop Med Hyg 2016; 94 (3): 489–93.
2. Заславский Д.В., Андриенко Е.М., Александрова И.Ю. и др. Верификация лейшманиоза кожи. Вестник дерматологии и венерологии. 2014; 5: 91–5.
[Zaslavskii D.V., Andrienko E.M., Aleksandrova I.Iu. et al. Verification of cutaneous leishmaniasis. Vestnik dermatologii i venerologii. 2014; 5: 91–5 (in Russian).]
3. Hotez P, Lo N. Neglected tropical diseases: public health control programs and mass drug administration. In: Ryan E, Hill D, Solomin T et al. (Eds.) Hunter’s Tropical Medicine and Emerging Infectious Diseases. 2020. 10th Ed.; 209–13.
4. Garcia L. Leishmaniasis. In: Cherry J, Harrison G, Kaplan Sh et al. (Eds.) Feigin and cherry’s textbook of pediatric infectious diseases. 8th Ed. 2019; 2178–86.e2.
5. Leishmaniasis. 2014. http://www.who.int/topics/leishmaniasis/en/
6. Murray H, Berman J, Davies C et al. Advances in leishmaniasis. Lancet 2005; 366 (9496): 1561–77.
7. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Centers for Diseases Control and Prevention. https://www.cdc.gov/parasites/leishmaniasis/epi.html
8. Gradoni L. Leishmaniasis. In: Kellerman R, Rakel D (Eds.). Conn’s Current Therapy. 2020; 577–80.
9. De Menezes J, Koushik A, Das S et al. Leishmania infection inhibits macrophage motility by altering F-actin dynamics and the expression of adhesion complex proteins. Cell Microbiol 2017; 19 (3). DOI: 10.1111/cmi.12668
10. Ready P. Biology of phlebotomine sand flies as vectors of disease agents. An Rev Entomol 2013; 58: 227–50.
11. Pace D. Leishmaniasis. J Infect. 2014; 69; Suppl. 1: 10–8. DOI: 10.1016/j.jinf.2014.07.016
12. Hewitt S, Reyburn H, Ashford R, Rowland M. Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: vertical distribution of cases in apartament blocks. Transact Royal Society Tropical Med Hyg 1998; 92 (3): 273–4.
13. World Health Organization (WHO). First WHO report on neglected tropical diseases 2010: working to overcome the global impact of neglected tropical diseases. Geneva, 2010.
14. Kevric I, Cappel M, Keeling J. New World and Old World Leishmania Infections. A Practical Review. Dermatol Clin 2015; 33 (3): 579–93.
15. Banuls A, Hide M, Pruqnolle F. Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol 2007; 64: 1–109.
16. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5 (11): 873–82.
17. Sakthianandeswaren A, Foote S, Handman E. The role of host genetics in leishmaniasis. Trends Parasitol 2009; 25 (8): 383–91.
18. Zhang W, Matlashewski G. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol 2001; 39 (4): 935–48.
19. Okwor I, Uzonna J. Social and Economic Burden of Human Leishmaniasis. Am J Trop Med Hyg 2016; 94 (3): 489–93.
________________________________________________
2. Zaslavskii D.V., Andrienko E.M., Aleksandrova I.Iu. et al. Verification of cutaneous leishmaniasis. Vestnik dermatologii i venerologii. 2014; 5: 91–5 (in Russian).
3. Hotez P, Lo N. Neglected tropical diseases: public health control programs and mass drug administration. In: Ryan E, Hill D, Solomin T et al. (Eds.) Hunter’s Tropical Medicine and Emerging Infectious Diseases. 2020. 10th Ed.; 209–13.
4. Garcia L. Leishmaniasis. In: Cherry J, Harrison G, Kaplan Sh et al. (Eds.) Feigin and cherry’s textbook of pediatric infectious diseases. 8th Ed. 2019; 2178–86.e2.
5. Leishmaniasis. 2014. http://www.who.int/topics/leishmaniasis/en/
6. Murray H, Berman J, Davies C et al. Advances in leishmaniasis. Lancet 2005; 366 (9496): 1561–77.
7. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Centers for Diseases Control and Prevention. https://www.cdc.gov/parasites/leishmaniasis/epi.html
8. Gradoni L. Leishmaniasis. In: Kellerman R, Rakel D (Eds.). Conn’s Current Therapy. 2020; 577–80.
9. De Menezes J, Koushik A, Das S et al. Leishmania infection inhibits macrophage motility by altering F-actin dynamics and the expression of adhesion complex proteins. Cell Microbiol 2017; 19 (3). DOI: 10.1111/cmi.12668
10. Ready P. Biology of phlebotomine sand flies as vectors of disease agents. An Rev Entomol 2013; 58: 227–50.
11. Pace D. Leishmaniasis. J Infect. 2014; 69; Suppl. 1: 10–8. DOI: 10.1016/j.jinf.2014.07.016
12. Hewitt S, Reyburn H, Ashford R, Rowland M. Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: vertical distribution of cases in apartament blocks. Transact Royal Society Tropical Med Hyg 1998; 92 (3): 273–4.
13. World Health Organization (WHO). First WHO report on neglected tropical diseases 2010: working to overcome the global impact of neglected tropical diseases. Geneva, 2010.
14. Kevric I, Cappel M, Keeling J. New World and Old World Leishmania Infections. A Practical Review. Dermatol Clin 2015; 33 (3): 579–93.
15. Banuls A, Hide M, Pruqnolle F. Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol 2007; 64: 1–109.
16. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5 (11): 873–82.
17. Sakthianandeswaren A, Foote S, Handman E. The role of host genetics in leishmaniasis. Trends Parasitol 2009; 25 (8): 383–91.
18. Zhang W, Matlashewski G. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol 2001; 39 (4): 935–48.
19. Okwor I, Uzonna J. Social and Economic Burden of Human Leishmaniasis. Am J Trop Med Hyg 2016; 94 (3): 489–93.
Авторы
Г.И. Волкова1,2, М.И. Смирнова1, В.М. Делягин*1
1 ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, Москва, Россия;
2 Российская детская клиническая больница ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
*delyagin-doktor@yandex.ru
1 Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia;
2 Russian Children's Clinical Hospital, Pirogov Russian National Research Medical University, Moscow, Russia
*delyagin-doktor@yandex.ru
1 ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, Москва, Россия;
2 Российская детская клиническая больница ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
*delyagin-doktor@yandex.ru
________________________________________________
1 Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia;
2 Russian Children's Clinical Hospital, Pirogov Russian National Research Medical University, Moscow, Russia
*delyagin-doktor@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.